dr. brufsky on the fda approval of olaparib in brca breast cancer
Published 6 years ago • 198 plays • Length 2:46Download video MP4
Download video MP3
Similar videos
-
1:06
dr. brufsky on challenges in breast cancer
-
1:15
dr. brufsky on reducing the cost of care in breast oncology
-
0:30
dr. brufsky on adjuvant bisphosphonates for patients with breast cancer
-
1:04
dr. brufsky on the disease-free survival of aromatase inhibitors for breast cancer
-
0:49
dr. tung discusses the role of olaparib in breast cancer
-
1:07
dr. brufsky on challenges facing biosimilars in breast cancer
-
1:49
dr. brufsky on multiparametric genomic assays in breast cancer
-
5:43
using olaparib in gbrca1/2 breast cancer
-
1:30
dr. brufsky on genomic assays for breast cancer
-
1:01
dr. brufsky on trastuzumab biosimilars in breast cancer
-
1:15
dr. robson on the toxicity profile of olaparib in breast cancer
-
3:31
fda d.i.s.c.o. burst edition: fda approval of lynparza (olaparib), with abiraterone and prednison...
-
2:21
olaparib: predicting response in breast cancer
-
7:21
fda approval of ribociclib for metastatic breast cancer
-
2:20
dr. brufsky on choosing when to do a multiparameter genomic assay
-
0:35
dr. brufsky discusses bevacizumab benefits in tnbc
-
0:57
dr. brufsky on biosimilars being explored in oncology
-
0:38
dr. petrylak on fda approval of pembrolizumab in bladder cancer
-
5:49
perspectives on the olympia study of adjuvant olaparib in early breast cancer | nadine tung